Department of Pharmacy Practice, Marshall B. Ketchum University College of Pharmacy, Fullerton, California, USA.
Emergency Medicine, Loma Linda University Medical Center, Loma Linda, California, USA.
Pharmacotherapy. 2021 Jul;41(7):598-607. doi: 10.1002/phar.2596. Epub 2021 Jun 1.
Recent studies have identified that reduced alternative intravenous insulin doses, such as 5 units or 0.1 units/kg, may reduce the risk of hypoglycemia compared to standard doses of 10 units in patients treated for hyperkalemia. However, some studies suggest that these alternative doses may reduce the ability to lower serum potassium. This study was performed to determine the impact of alternative insulin dosing on hypoglycemia and potassium reduction in patients with hyperkalemia.
Meta-analysis.
PubMed/MEDLINE, CENTRAL, Ovid, and ClinicalTrials.gov were searched from inception through November 2020.
Patients treated with standard (10 units) or alternative (<10 units) insulin dosing strategies for hyperkalemia. Only studies that evaluated hypoglycemia (serum glucose <70 mg/dl), severe hypoglycemia (serum glucose <50 mg/dl), and potassium reduction post-treatment were included in the meta-analysis. All articles were assessed for bias using the Cochrane Risk of Bias Assessment Tool and Newcastle-Ottawa scales for randomized prospective trials and retrospective trials, respectively.
None.
Ten retrospective cohort studies (n = 3437) were included and had low- or moderate-risk of bias. Alternative insulin dosing strategies included 5 units, 0.1 units/kg, and <10 units. Alternative dosing had lower pooled odds of hypoglycemia (odds ratio [OR] 0.55, 95% confidence interval [CI] 0.43-0.69, I = 8%) and severe hypoglycemia (OR 0.41, 95% CI 0.27-0.64, I = 0%). No difference in potassium reduction was detected (mean difference -0.02 mmol/L, 95% CI -0.11-0.07, I = 53%).
Alternative insulin dosing strategies for hyperkalemia management resulted in less hypoglycemia and severe hypoglycemia without compromising potassium reduction compared to standard dose. Prospective studies are needed to confirm these findings.
最近的研究表明,与标准剂量 10 单位相比,降低替代静脉胰岛素剂量(如 5 单位或 0.1 单位/公斤)可能会降低治疗高钾血症患者的低血糖风险。然而,一些研究表明,这些替代剂量可能会降低降低血清钾的能力。本研究旨在确定替代胰岛素剂量对高钾血症患者低血糖和钾降低的影响。
荟萃分析。
从建库到 2020 年 11 月,通过 PubMed/MEDLINE、CENTRAL、Ovid 和 ClinicalTrials.gov 进行了搜索。
接受标准(10 单位)或替代(<10 单位)胰岛素剂量治疗高钾血症的患者。只有评估低血糖(血清葡萄糖<70mg/dl)、严重低血糖(血清葡萄糖<50mg/dl)和治疗后钾降低的研究被纳入荟萃分析。所有文章均使用 Cochrane 风险偏倚评估工具和纽卡斯尔-渥太华量表分别评估随机前瞻性试验和回顾性试验的偏倚风险。
无。
纳入了 10 项回顾性队列研究(n=3437),这些研究的偏倚风险较低或中度。替代胰岛素给药方案包括 5 单位、0.1 单位/公斤和<10 单位。替代给药方案发生低血糖的 pooled 比值比(OR)为 0.55(95%置信区间 [CI] 0.43-0.69,I = 8%)和严重低血糖的 pooled 比值比(OR)为 0.41(95% CI 0.27-0.64,I = 0%)显著更低。钾降低方面无差异(平均差值-0.02mmol/L,95% CI -0.11-0.07,I = 53%)。
与标准剂量相比,治疗高钾血症的替代胰岛素给药方案可降低低血糖和严重低血糖的发生,同时不影响钾的降低。需要前瞻性研究来证实这些发现。